IXHL Incannex Healthcare
- 2.559
- +0.009+0.35%
Incannex Healthcare News
FDA Experts Weigh In On Incannex's CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder
Incannex Healthcare Inc. (NASDAQ:IXHL), a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food a
Incannex Complete Successful Pre-IND Meeting With the FDA for CannQuit-O for Treatment of Opioid Use Disorder
MELBOURNE, Australia and NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to
Incannex Healthcare Inc. Quarterly Update, Q1 2024
MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), ('Incannex' or the 'Company'), is pleased to prov
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P
Psychedelic-Assisted Therapy Advancements Create A New Horizon For Mental Health In Colorado
Recent advancements within the field of mental health with the use of psilocybin-assisted therapy, as well as Colorado's forward-thinking legislation about this therapy, have proven exciting.Psilocybi
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c
Incannex Healthcare Appoints New CFO and Secretary
Incannex Healthcare Tapped Treasurer and Controller Joseph Swan to Additional Role of CFO, Effective February 29 After Madhukar Bhalla Decided to Retire
Madhukar Bhalla, Chief Financial Officer and Secretary of Incannex Healthcare Inc. (the "Company"), recently notified the Company of his decision to resign from his positions effective as of February
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized AnxietyPsilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits f
Ampio Pharmaceuticals, Ironwood, Incannex Among Healthcare Movers
KLIC, IRWD and GRFS Among Pre-market Losers
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
Psilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits for Generalized Anxiety Disorder (GAD.) With variable symptoms, the condition typically involves a per
What's Going On With Incannex Stock?
Incannex Healthcare Inc. (NASDAQ:IXHL) shares are trading higher Wednesday after the company announced its Psi-GAD1 trial met its primary endpoint.The Details:Incannex said that its Phase 2 Psi-GAD1 c
Incannex Healthcare Shares Halted On Circuit Breaker To The Downside, Stock Now Up 72.8%
Incannex Healthcare Shares Halted On Circuit Breaker To The Downside, Stock Now Up 72.8%
Incannex Healthcare Shares Soar Premarket on Psilocybin Study
By Colin Kellaher Incannex Healthcare shares surged more than 80% in premarket trading Wednesday after the biotechnology company reported positive top-line results from a Phase 2 study of psilocybin
Incannex Stock Surges as Anxiety Disorder Study Meets Primary Goal
Market-Moving News for February 28th
BYND: 105% | Beyond Meat shares are trading higher after the company reported mixed Q4 financial results.FLYW: 31% | Flywire shares are trading higher after the company reported better-than-expected Q
Incannex Announces Positive Topline Results From Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
Highlights: PsiGAD1 trial achieves primary endpoint; PsiGAD psilocybin-assisted therapy demonstrated a statistically significant HAM-A reduction of 12.8 points from baseline, representing a 9.2-point improvement over
SNCR, JANX and GBNH Among Mid-day Movers
Analysis
Price Target
No Data
